Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Zhejiang Tianyu Pharmaceutical Co., Ltd.
  6. Summary
    300702   CNE1000034X1

ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.

(300702)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
57 51.12 49.45 51.4 49.09 Last
9346896 7120986 3986733 5813500 6735289 Volume
+5.44% -10.32% -3.27% +3.94% -4.49% Change
Estimated financial data (e)
Sales 2021 2 680 M 423 M 423 M
Net income 2021 524 M 82,7 M 82,7 M
Net Debt 2021 - - -
P/E ratio 2021 21,2x
Yield 2021 -
Sales 2022 3 330 M 525 M 525 M
Net income 2022 716 M 113 M 113 M
Net Debt 2022 - - -
P/E ratio 2022 16,1x
Yield 2022 -
Capitalization 17 082 M 2 695 M 2 695 M
Capi. / Sales 2021 6,37x
Capi. / Sales 2022 5,13x
Nbr of Employees 4 309
Free-Float 37,6%
More Financials
Company
Zhejiang Tianyu Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of chemical raw materials. The Company operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high... 
Sector
Pharmaceuticals
Calendar
04/28Earnings Release
More about the company
Ratings of Zhejiang Tianyu Pharmaceutical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year End..
CI
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces 2020 Final Profit Distribution Plan ..
CI
2021ZHEJIANG TIANYU PHARMACEUTICAL : Pharma to List Over 1 Million Restricted Shares
MT
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Approves Cash Dividend for the 2020
CI
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Proposes Final Dividend for 2020
CI
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter..
CI
2021ZHEJIANG TIANYU PHARMACEUTICAL : Raises $138 Million from Private Share Sale
MT
2020Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that it has received CNY 899.999995 ..
CI
2020ZHEJIANG TIANYU PHARMACEUTICAL CO., : 300702) added to Shenzhen Stock Exchange Component ..
CI
2020ZHEJIANG TIANYU PHARMACEUTICAL CO., : 300702) added to Shenzhen Stock Exchange Component ..
CI
2020Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2020ZHEJIANG TIANYU PHARMACEUTICAL CO., : 300702) added to S&P Global BMI Index
CI
2020Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year End..
CI
2020Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 900 m..
CI
More news
News in other languages on ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. annonce la mise en ťuvre du plan de distributi..
2021Zhejiang Tianyu Pharma va inscrire à la cote plus d'un million d'actions à négociation ..
2021La société Zhejiang Tianyu Pharmaceutical Co., Ltd. approuve le dividende en espèces po..
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. propose un dividende final pour 2020
2021Zhejiang Tianyu Pharmaceutical lève 138 millions de dollars grâce à une vente d'actions..
More news
Chart ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
Duration : Period :
Zhejiang Tianyu Pharmaceutical Co., Ltd. Technical Analysis Chart | 300702 | CNE1000034X1 | MarketScreener
Technical analysis trends ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 49,09 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Yong Jun Tu Chairman & General Manager
Yan Wang Chief Financial Officer & Board Secretary
Cheng Ma Chairman-Supervisory Board
Hai Zhi Ren Independent Director
Ji Yuan Shi Independent Director